INTRODUCTION

66
There are 239,000 new cases and 152,000 deaths from ovarian cancer (OC) worldwide 67 annually. [1] Advances in treatment have led to only small improvements in survival over the 68 last 10-20 years, and it remains the commonest cause of deaths from gynaecological 69 cancer. [2] Screening for OC has not yet been shown to reduce mortality, [3] and the most 70 effective risk-reducing procedure currently available is surgical removal of both tubes and 71 ovaries. Risk reducing salpingo-oophorectomy (RRSO) has been found to have a hazard ratio 72 (HR) being 0.06 (CI:0.02,0.17) in a low-risk population [4] and 0.21 (CI:0.12,0.39) in 73 BRCA1/BRCA2 carriers. [5] However, currently it is only routinely available to women from 74 high-risk families, such as those carrying high penetrance BRCA1/BRCA2 and mismatch-75 repair gene mutations (lifetime OC risk ≥10%), for whom the cost-effectiveness [6] of such an 76 approach is well established.
78
In the general (low-risk) population, the OC risk distribution includes women with both 79 higher (but <10%) and lower than the average lifetime risk estimates (1.3%-2%). [2, 7] . A 80 number of lifestyle, reproductive and medical factors such as contraceptive pill use, tubal 81 ligation, parity, endometriosis, subfertility, age and family-history have been shown to be 82 associated with OC risk. In addition 17 common genetic variants influencing OC risk have 83 been identified through genome wide association studies (GWAS) and other large-scale 84 genotyping efforts. [8] Although the risk with each individual variant is small, women who 85 carry multiple risk alleles have a 2-3 fold higher risk estimate than those with a low polygenic 86 load. [9, 10] RRSO has not been formally evaluated as a risk reducing option in these lower 87 risk populations and the 'risk threshold' at which this intervention may become cost-effective 88 for prevention of sporadic OC has not been defined. As the median age of diagnosis of 89 sporadic OC is >65 years, [11] RRSO could be restricted to postmenopausal women >50 90 years age. 
METHODS
103
A decision-analytic model ( Figure-1 given a probability and values for each outcome are calculated. We assume that the risk 116 threshold for the woman has already been identified through existing risk prediction 117 algorithms based on known risk factors and these risk prediction costs are not included.
118
Model outcomes include OC and excess deaths from mainly cardiovascular causes. [4] 119 120
In line with guidelines on the reference case for economic evaluation from the National
121
Institute for Health and Care Excellence(NICE), all costs and outcomes were discounted at 122 3.5%. [12] 123 124
Probabilities
125
All model pathway probabilities are detailed in Table- gives an absolute increase in risk=0.03%% (CI:-0.58%,0.65%) and numbers needed to harm 
Costs
137
All costs are described in Table- survival, the probability of death was assumed to be same as the general population. 
Analysis
169
The probability of being in a branch of the decision-model was calculated by multiplying 170 together the path probabilities. The total costs and effects in terms of life-years and QALYs 
174
By comparing this ICER with the £20,000-£30,000/QALY cost-effectiveness threshold used 175 by NICE, [22] we determined whether 'offering RRSO' to women above a certain risk confidence-intervals/range, where available, or by +/-10%, and costs were varied by +/-30%.
181
In addition to the one-way sensitivity results, a probabilistic sensitivity analysis (PSA) was 
RESULTS
193
The discounted and undiscounted survival (life-years), lifetime costs, and QALYs for each 194 branch in the decision model at the different OC risk thresholds of 2%, 4%, 5%, 6%, 8% and 195 10% are given in Table- The PSA results ( Figure-3 5% complication rate has been reported in high risk women. [36, 37] It is important that this risk thresholds is expected and reassuring. It is interesting that the model is highly sensitive to 298 the lower limit of the utility-score for RRSO at all risk levels. This is probably because the 299 standard deviation is large. Hence, there is need for further research on RRSO utility-scores 300 to better understand and improve the precision of its estimate. Of note nearly all published 301 work is on the pre-menopausal population where the impact on quality-of-life is different.
302
Separate utility-scores need to be developed for pre and postmenopausal RRSO.
304
The PSA undertaken is recommended by decision making bodies and adds to the robustness 305 of our results. [12] It permits simultaneous variation in probabilities of all parameters to fully 306 characterise model uncertainties and its effect on overall results. That 80-94% of simulations 307 on PSA were cost-effective for the risk thresholds ≥5% reconfirms the health-economic 308 benefit of RRSO at these risk levels for OC prevention. 
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Role of Funding Source
347
The study is not funded by any charity or grant. or range of all probability parameters described in Table-1/methods; and both lower and   378 upper values/limits of the cost and utility-score parameters given in Table 2 . Costs are varied 379 by +/-30%. Maximum value' represents outcomes for upper limit and 'Minimum value' 380 represents outcomes for lower limit of the parameter. or range of all probability parameters described in Table- Cost of CHD death 3277 *All costs were varied by +/-30% in one way sensitivity analysis NHS-national health service, NICE-national institutes for health and clinical excellence, , RRSO-risk reducing salpingo-oophorectomy,
Explanation
The cost of RRSO was based on national reference costs for an upper genital tract laparoscopic/endoscopic intermediate procedure. [38] Costs for ovarian cancer diagnosis and treatment were derived from national reference costs and a recent ovarian cancer guideline developed by NICE. [38, 39] We assumed that the cost of diagnosis to include a pelvic examination, ultrasound scan, CA125 test, CT scan, percutaneous biopsy and peritoneal cytology. The cost of treatment included the reference cost for a lower and upper genital tract very complex major procedure and administration of chemotherapy based on 6 cycles of carboplatin and paclitaxel treatment. It was assumed that in years-1 and -2 treated survivors would have a further three consultant visits, a CT scan and 4 CA125 tests each year. In years 3 to 5 post-surgery it was assumed that survivors would have 2 consultant visits and 2 CA125 tests. We were conservative in our cost-estimates and did not include costs for additional investigations, treatment of recurrence or management of complications in the analysis. Costs for terminal care for ovarian cancer were derived from end-of-life costs for cancer patients based on a report from the National Audit Office, UK. [40] In line with NICE recommendations future healthcare costs not associated with ovarian cancer were not considered. 473 474 
